---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-153667"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2024-06-04T23:59:59+00:00"
generated_at: "2026-06-01T06:34:47.932498+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium reports Phase 2 topline data for EQ101 in alopecia areata; 20% of completers achieved SALT ≤20

## Summary
- Of 25 completers (baseline SALT 35-100), 20% reached SALT ≤20 at week 24; mean SALT improvement 13.5%.
- In moderate-to-severe subgroup (n=17), 29% achieved SALT ≤20; mean improvement 18.4% from baseline.
- EQ101 well tolerated, no SAEs; 98.9% AEs Grade 1/2; common: URI, headache, fatigue; two Grade 3 events.
- Preliminary PD data show reduction of CD132 on CD8 and NK cells, consistent with target engagement.

## SEC filing metadata
- accession: 0001193125-24-153667
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2024-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312524153667/0001193125-24-153667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312524153667/d842173d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-153667
- JSON: https://secwatch.observer/filing/0001193125-24-153667.json
- Plain text: https://secwatch.observer/filing/0001193125-24-153667.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.